The ability to measure IDO activity in the peripheral blood of cancer patients76 allows researchers to prospectively map and characterise potential groups of patients who may benefit from modified treatment doses (eg radiotherapy) based on IDO immune status. The gene discussed is IDO1; the disease is cancer.